The Department of Health and Human Services (HHS) is looking to appeal a judge’s decision to block the administration’s plan to require drug companies include a drug’s list price in television ads, FierceHealthcare reports.
Officials, according to the report, have argued that the proposal would be a boon to transparency, though some skeptics have suggested that including prices in ads would only confuse consumers.
Judge Amit Mehta said that while the policy could “very well be an effective tool” in wrangling drug prices, the agency acted out of its sphere of authority when it finalized the proposed rule.
To read the full report on FierceHealthcare, click here.
